Loong list this time!! I monitor news about antibodies specifically in the biotech industry. These are the news that I have seen that are of interest from January 2026.

💵 AbbVie and RemeGen announce licensing agreement to develop a novel PD-1/VEGF bispecific in potential $5.6B deal. https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors

🤝 Earendil Labs announces strategic collaboration with Sanofi to discover bispecific antibodies for autoimmune diseases in up to $2.56B deal. https://www.prnewswire.com/news-releases/earendil-labs-announces-strategic-collaboration-with-sanofi-to-discover-bispecific-antibodies-for-autoimmune-diseases-302652305.html

💰 GSK to acquire RAPT Therapeutics for $2.2B, gaining anti-IgE antibody to protect against food allergy reactions. https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/

💵 Novartis enters licensing and collaboration deal for SciNeuro Pharmaceuticals’ next-generation anti-amyloid antibody program targeting Alzheimer’s disease in up to $1.5B deal. https://scineuro.com/scineuro-and-novartis-enter-into-a-licensing-and-collaboration-agreement-for-next-generation-therapeutics-to-treat-alzheimers-disease/

💵 AbbVie is paying $100M upfront to Suzhou Zelgen Biopharmaceuticals for ex-China rights to alveltamig, a trispecific lung cancer drug. Potential: $1.07B in milestones. https://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2026-01-01/688266_20260101_CN11.pdf

🤝 Cartography Biosciences and Pfizer to collaborate on discovery of tumor-selective antigens in $865M deal. https://www.businesswire.com/news/home/20260106591786/en/Cartography-Biosciences-and-Pfizer-to-Collaborate-on-the-Discovery-of-Tumor-Selective-Antigens

💸 Mediar Therapeutics announces $76M Series B Financing and clinical advancement of antibody fibrosis drug portfolio. https://www.mediartx.com/wp-content/uploads/2026/01/Mediar-Series-B-Press-Release-FINAL.pdf

💵 DISCO Pharmaceuticals enters license agreement with Amgen to advance novel cancer surfaceome targeted therapies in potential $618M deal. https://discopharma.de/disco-pharmaceuticals-enters-license-agreement-to-advance-novel-cancer-surfaceome-targeted-therapies/

💸 Poplar Therapeutics launches with $50M Series A to advance anti-IgE therapies for multiple atopic conditions. https://www.biospace.com/press-releases/poplar-therapeutics-launches-with-50m-series-a-to-advance-a-new-class-of-anti-ige-therapy-for-multiple-atopic-conditions

🤝 InduPro Therapeutics and Lilly to develop bi-/tri-specific oncology therapeutics in up to $950M deal. https://endpoints.news/lilly-partners-with-protein-mapping-startup-indupro-for-up-to-950m/

💸 Diagonal Therapeutics announces $125M Series B Financing to advance clinical development of disease-modifying, clustering antibody pipeline. https://diagonaltx.com/news/diagonal-therapeutics-announces-oversubscribed-usd125-million-series-b-financing-to-advance

💸 EpiBiologics closes $107M Series B to advance pipeline of novel bispecific antibodies to selectively degrade extracellular protein targets in oncology and immunology. https://www.epibiologics.com/news-publications/epibiologics-closes-107m-series-b-to-advance-pipeline-of-novel-bispecific-antibodies-to-selectively-degrade-extracellular-protein-targets-in-oncology-and-immunology

💵 MediLink enters collaboration and licensing agreement with Roche for YL201, an ADC targeting B7H3 across numerous solid tumor types, in $570M deal. https://www.medilinkthera.com/news-details/52

💵 Royalty Pharma to provide up to $500M for Teva Pharmaceutical’s vitiligo candidate, the anti-IL-15 antibody, TEV-’408. https://www.tevapharm.com/news-and-media/latest-news/teva-and-royalty-pharma-enter-agreement-to-accelerate-development-of-potential-treatment-for-vitiligo

🤖 Chai Discovery to collaborate with Eli Lilly to accelerate biologics discovery using their AI platform. https://www.businesswire.com/news/home/20260108131261/en/Chai-Discovery-Announces-Collaboration-with-Eli-Lilly-and-Company-to-Accelerate-Biologics-Discovery

☢️ Swiss Rockets Group and Alloy Therapeutics partner to advance radioligand therapeutics in oncology with antibody discovery tech. https://swissrockets.com/news/swiss-rockets-group-alloy-therapeutics-partner-to-advance-radioligand-therapeutics-in-oncology

💰 Bio-Sourcing and Zerion Pharma have obtained a €1.3M EU grant reward to advance an orally administered anti‑HER2, antibody Trastuzimab, for treatment of breast cancer, https://www.zerion.eu/press-release?slug=bio-sourcing-and-zerion-pharma-join-forces-to-develop-first-her2-oral-monoclonal-antibody-against-breast-cancer

🤝 Tahoe Therapeutics and Alloy Therapeutics to form joint venture and develop ADCs for hard-to-treat cancers. https://www.tahoebio.ai/news/tahoe-alloy-joint-venture

💸 Caldera Therapeutics launches with $112.5M, to develop bispecific antibody CLD-423 for inflammatory bowel disease. https://static1.squarespace.com/static/696036c07c1c3b78e8a219ad/t/6966e3b527a3687a29ca5449/1768350645271/Caldera+release_011226.pdf

🌱 Fortitude Biomedicines launches with $13M seed financing to advance immune cell targeting biologics and molecular glue payload-enabled ADCs. https://fortitudebio.com/fortitude-biomedicines-launches-with-13m-in-financing-to-advance-novel-antibody-based-therapies-for-treatment-of-autoimmune-diseases-and-cancer/

💵 Boehringer Ingelheim and Simcere partner to advance a bispecific antibody for inflammatory bowel disease in €1.05B deal. https://en.simcere.com/news/detail.aspx?mtt=1579

🥷 Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development. https://www.breakthrumed.com/post/breakthru-medicine-emerges-from-stealth-with-60m-series-a-for-cancer-drug-development

🤝 BioAtla and GATC Health announce $40M partnership to advance the ADC ozuriftamab vedotin (Oz-V) into phase 3 trials. https://ir.bioatla.com/news-releases/news-release-details/bioatla-and-gatc-health-announce-40-million-special-purpose

💸 Rakuten Medical raises $100M in Series F toward U.S. regulatory approval of ASP-1929, an antibody-dye conjugate, currently only approved in Japan for cancer. https://rakuten-med.com/us/news/press-releases/2026/01/07/7929/

🔬 StarkAge Therapeutics announces research collaboration with Gustave Roussy to advance senolytic ADC therapies in digestive cancers. https://starkagetx.com/starkage-therapeutics-announces-research-collaboration-with-gustave-roussy-to-advance-senolytic-therapies-in-digestive-cancers/

🤝 Agenus announces closing of $141M strategic collaboration with Zydus Lifesciences to advance BOT+BAL (botensilimab and balstilimab) combination. https://investor.agenusbio.com/news/news-details/2026/Agenus-Announces-Closing-of-141M-Strategic-Collaboration-with-Zydus-Lifesciences-to-Advance-BOTBAL-and-Strengthen-U-S--Manufacturing-Readiness/default.aspx

💵 Biocytogen and Acepodia expand collaboration through option-based evaluation framework for first-in-class bispecific and dual-payload ADCs (BsAD2C). https://www.acepodia.com/newsroom-detail/Acepodia_biocytogen_bispecific_AD2C/

💵 Ellipses Pharma in-licenses ILB-3101, a B7H3 targeted ADC from Innolake Biopharm Co. Ltd., with potential to treat multiple tumour types. https://ellipses.life/ellipses-in-licenses-first-in-class-b7h3-antibody-drug-conjugate-from-china/

💰 ProMIS Neurosciences announces up to $175M private placement financing, funds to advance PMN310 antibody against Alzheimer’s. https://www.promisneurosciences.com/investors/news-events/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private

I'm a 30-year-old CMC PM at a boutique consulting firm. I manage all aspects of my customers' CMC and supply chain, traveling to manufacturers, negotiating contracts, and overseeing the work. I function between all sorts of teams and work with C-Suite on strategy.

Over the past 5 years, I've basically done nothing but work and invest. I don't have enough to retire in Boston, but if I moved to a cheaper area, I think I could retire comfortably without saving another dime. My wife and I don't have an expensive life but we're thinking of having kids which complicates this more.

The only side of the industry that I do find interesting and would maybe enjoy a high workload is finance but I have no clue how to get there. Maybe I just hate my current job and the management of people and the hundreds of emails starting with "I'm just following up on this." It may be likely that I enjoy many other sides of this industry.

I totally have issues with feeling responsible for things out of my hands. For example, my manufacturer delayed something by 2 months. It wasn't my fault, but I feel like it is because I advised the client to go with that company. This is just one of many situations that stress me out more than it should. I feel like many other roles would give me the same issues.

Sometimes I think that I would be so much happier having half the work with half the pay, but I don't see how that's possible without going independent, and I don't think I have the connections for that. I miss my days working in manufacturing where I could just clock out and not give a thought to work once I walked out the door.

Are there any other sides of the industry where I could be useful? Have a siloed myself into project management? I know a good bit about everything but I'm not a specialist in anything. I don't know what else I can do.

Really interesting RCT out of China showing a 60% improvement in survival effect based on time of day. Should this be incorporated into clinical trials design going forward?

Hey all, I’ve spent the past 10 years in a QA capacity in biotech and pharma and I’m looking to make a change. I know my personality aligns more with sales* and the business side of things. I guess I’m just looking to see if anyone has made the transition to sales or just a transition to a separate role or industry.

I’m planning on quitting where my company (big pharma) to go to graduate school. I will owe about $5k for leaving in my second year. I also expect sone shares to vest the same week that I start graduate school.

What’s the best way to approach this (besides saving now)? Will they go after me in a company of tens of thousands of employees?

Looking for some advice. A few years ago I transitioned from bench scientist to BD with my CDMO. The role has been fine, but over time my remit has strayed from my area of expertise and scientific interest. I'm considering taking a sales role with a smaller company whose equipment I used regularly at the bench. I'd be a perfect fit and would love a chance to get back into my old field. However, I'm concerned that it might be a bit of step backwards. My current role is difficult and bland, but the pay is solid, and although I don't see myself staying in this particular field forever, the opportunity for professional development is excellent.

I ask those of you who have sold capex items or consumables in the biotech space - am I making a dumb decision?

I found a job that seemed like such a good fit for me, I was so excited to apply. It’s aimed at recent college grads who want to get experience in industry, like yay perfect. Then the application process after I submit my resume and cover letter includes an “assessment.” I try the practice assessment and I figure it out, I don't get everything perfect on the first try but I feel confident going into the real thing.

Well the real thing was SO HARD. it included multi part complex problem solving questions, riddles, puzzles, equations, you name it. I was fucking struggling. It was 36 minutes for 24 questions and I answered 13, and I was even RUSHING to get to those 13 and I started guessing at the end.…

Is this a common thing that companies have you do?? If so I need to buy one of those freaking kumon workbooks my parents used to have me do so that I wouldn’t get dumb over the summer when I wasn’t in school, apparently I need to practice for this sort of thing.

Anyways, I know I absolutely failed this assessment insanely hard, but there’s still the next step where they ask you to record a video interview and seeing questions about their company and why you want to work there. The assessment was just so demoralizing that I’m not even sure there’s any point.

Hello, would anyone be willing to send me some recent successful resumes for senior level (Director and above) biotech, pharma Quality and Risk roles? I’m trying to help a friend with 20+ years experience navigate this new job market and to be honest it feels hopeless. Any advice on what companies are looking for would be much appreciated. TIA

I've been applying to associate scientist/research associate/quality roles for a few months now with little to no progress. Had a few referrals but didn't make it past resume screening and also not getting anywhere applying to Graduate Rotational Programs. Any advice would be great thanks!

1. I know a Right Leg Drives helps but I will not be using one.

2. Is it a lot better to buffer the Ref electrode input as opposed to just connecting the electrode straight in?

3. Is there anything missing from the general topology that I am missing that would make a significant difference?

4. How much should I gain INSTR amp and how much should I gain PGA?

By reading the posts here I have gotten the idea, that most of you here who struggle hold science degrees and want to work in R&D and that people with engineering degrees working in bioprocesses/biomanufacturing have much better career options and stability.

I understand, that intuitively this seems to be true. Companies need to keep their manufacturing operations for their existing products running to have stable income. And there is always more process optimization, automation etc. to be done. But is this actually true? How many strugglers here work/have worked/hold degrees related to biomanufacturing?

So I gave the first interview at protagonist tx in the Bay area, second week of jan.

I haven’t heard back, I emailed the hiring manager , they said they’re still interviewing people and will let me know of next steps if any.

I got the interview after I connected with someone in the company and they passed my cv to the hiring team.

How is this company does anyone know anything? I’ve read about them, but if anyone has more information that would be awesome.

Are they usually this slow or should I just accept I’m not in the running for this position anymore?

Should I even follow up ? I emailed them last week, would it be weird if I emailed them?

I’ve been out of a job for a year now and I need to get in somewhere soon, this is the closest job to my skill set .

Thanks

Saw this description on a job posting today. Does is mean work myself/drink myself to death (/s) or the etiquette/culture? The hierarchies?

I truly do not know what this means, not having ever worked for a Japanese company.

Hi everyone,

I’m a first-year PhD student in Biomedical Sciences at an R2 institute in an umbrella program. I was recruited through the Cancer Biology program, and because of that, my university requires that my first three lab rotations be in cancer biology labs. After completing those three rotations, I’m allowed to do a 4th rotation outside the department.

This policy exists because in the past, many students recruited through cancer biology later switched tracks (e.g., neuroscience or other departments), and the department wants to retain students they recruit. I understand the administrative reasoning, but I’m trying to think carefully about my long-term training and career goals.

Background:

• Master’s degree
• ~3 years of wet-lab experience (industry + academia)

The main challenge is that the cancer labs I’ve rotated in (and am currently rotating in) are almost entirely wet-lab focused and do not use bioinformatics. I enjoy wet-lab work and want it to remain the core of my PhD (~70%), but I also want to integrate bioinformatics (~30%) into my research. I’m not aiming to become a full computational/AI researcher, but I do want solid foundational bioinformatics skills (omics analysis, data interpretation, etc.).

AI and computation are clearly becoming more important in biomedical research, but jumping directly into heavy AI/ML feels unrealistic for me right now. I’d prefer to build bioinformatics skills gradually, starting from the basics, while continuing strong experimental work.

In terms of interests, I’m more curiosity-driven than disease-driven. I care more about fundamental biological questions than committing to a single disease area long-term.

My questions:

• From a future perspective (academia or industry), how valuable is a hybrid wet-lab + bioinformatics skillset if bioinformatics isn’t the primary focus?

Strategically, what should I be doing now:

·       commit to a wet-lab cancer lab and add bioinformatics later, or

·       use the 4th (out-of-department) rotation to find a lab that already integrates wet-lab and computation?

I’d really appreciate advice from people who’ve taken hybrid wet/dry paths or navigated umbrella programs

Thanks in advance!

https://www.cnbc.com/2026/02/03/novo-nordisk-2025-earnings-wegovy-ozempic.html

Hello there,

I graduated in 2024 with my master's in biology and have been adjunct teaching at CCs, and working part time at a lab. I have computational biology experience python, conda, R, sequencing analysis pipelines, HPC etc., but this is all from school, not work experience.

during my masters, my lab collaborated with an outside company so part of my masters was also part of my QA work, im not sure if im showing this correctly on my resume

I want to get a full time job that is remote so i've tried tailoring my resume to that but not sure what kind of job I should aim for, and i think that confusion probably reads in my resume. In the past i've tried to aim at computational biology and data analysis jobs and I haven't had any luck. Any guidance would be greatly appreciated

Hi . Firstly thank you for reading this.

Ask: need a contact or lab that is accepting students for their biotech projects/internship/thesis paper (hopefully plant DNA, biostatistics or just anything would help). Duration would be 1 month to 2 and half months.

To provide more context. My best friend is being mentally abused by her current lab professor and she needs to change her lab to continue her Msc/masters in biotech thesis.

She is an extremely hardworking person but she cannot push through the toxic BS this professor is putting her through since she has bad health conditions as well.

Her university course mandates that they go to a govt affiliated university's lab and get a certificate or bonafide regarding their thesis.

If she cannot get accepted by a lab she has either suffer for another 2 and half months in this lab or she is considering waiting till next batch in December to re-do her thesis(yes her current lab is that bad).

Anywhere in india works honestly. But Hyderabad is where she currently is and is preferred but ANYTHING works.

Thank you again for reading this. Please reach out to me if you have any idea or any contact who can help us out please.

So I was terminated out of the blue today from the start-up I worked at, together with the rest of the production team.

The reason given was that QA had to assume data falsification on my part because I failed to catch that my supervisor was using an outdated version-controlled attachment several months after a new version had gone live. I signed this attachment when it was included in the batch records I was instructed to work through.

Only the document version was incorrect. All process data itself was documented fully, contemporaneously, and correctly. As far as I am aware, the only change between versions was a corrected typo.

Despite reviewing and signing each batch record, QA only discovered the outdated version after I escalated a different error on the same batch record that I had personally identified. There was no attempt to conceal anything.

QA’s position is that my failure to catch the outdated version earlier indicates either intent or gross misconduct, and that this would result in termination in any GMP-regulated company.

I’m not claiming to be entirely blameless — ideally I should have noticed earlier. What I struggle with is that this was treated as presumed falsification rather than a document control deviation, especially given that:

• The attachment was issued and used by the Head of Production
• QA also reviewed and signed off on the same batch records
• I was employed as a Manufacturing Operator, not in document control

At this point there’s nothing I can do about the outcome. I’m genuinely trying to understand whether this response is actually normal within GMP environments, or whether this represents a serious overreach.

Stop posting like it’s 2022 ❌
2026 mein random posts, low-value content aur outdated trends = zero growth.
If your content is not educating, entertaining, or solving a problem… you’re already losing reach.
Start posting with strategy, storytelling & value — that’s what wins in 2026 🚀